Blogs

FirstIgnite is supporting the commercialization of Worcester Polytechnic Institute’s metal cutting robot technology, which is a novel framework for cutting metal scrap using robots in unstructured environments. This process improves occupational safety and reduces dependence on low-cost labor for hazardous tasks. The benefits include enhanced safety and efficiency, reduced labor-intensive work, minimized need for scanning entire objects, and leveraging worker expertise.

This technology has applications in recycling decommissioned large metal structures, dismantling oil rigs and ships, and processing large engines and equipment. The global metal recycling market size was valued at $229.6 billion in 2021 and is expected to increase to $384 billion by 2030.

Worcester Polytechnic Institute’s metal cutting robot technology is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the Worcester Polytechnic Institute team, you can schedule a time directly on their team’s calendar here.

FirstIgnite is supporting the commercialization of the University of Missouri at St. Louis's Q3D device for detecting amblyopia in children. This non-invasive device is a hand-held, battery-powered electronic device that presents visual stimuli to a subject using calibrated LEDs. It is the first and only device that provides an immediate and accurate quantified measurement of visual suppression (in 0.1 to 3.0 log units) in patients as young as 3 years old and is both simple and inexpensive.

The Q3D device serves as a tool for optometrists, ophthalmologists, and technicians conducting amblyopia assessments. Additionally, it has potential applications in assessing and monitoring optic neuritis and TBI. The global market size for amblyopia was valued at $4.5 billion in 2021, and is projected to reach $6.25 billion by 2030.

The University of Missouri at St. Louis’s Q3D device for detecting amblyopia in children is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the University of Missouri at St. Louis team, you can schedule a time directly on their team’s calendar here.

FirstIgnite is supporting the commercialization of Stony Brook University’s microgrid controller technology, which uses software-defined control (SDC) architecture for microgrids. This architecture virtualizes traditionally hardware-dependent microgrid control functions as software services, resulting in cost savings, easier upgrades, and improved performance by separating these functions from the underlying hardware infrastructure.

This technology has applications in the energy sector, including microgrids and distributed energy resources integration, smart grid management, and resilient and adaptive electricity networks. The global microgrid market is expected to increase from $8.74 billion in 2022 to $23.49 billion by 2029.

Stony Brook University’s microgrid controller technology is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the Stony Brook University team, you can schedule a time directly on their team’s calendar here.

FirstIgnite is supporting the commercialization of Stony Brook University’s monoclonal antibody technology, which targets wzi29, a major capsular polysaccharide (CPS) expressed by carbapenem-resistant Klebsiella pneumoniae (CR-Kp), providing a therapy for the heterogeneous CPS serotypes of CR-Kp. The technology shows cross-reactivity and efficacy against three most prevalent CR-Kp types, is effective both pre- and 4 hours post-infection, and reduces CR-Kp lung burden and dissemination.

This technology is applicable to the treatment of Klebsiella infections. The bacterial infection market was worth $ 72.0 billion in 2021 and is expected to increase to $138.28 billion by 2029.

Stony Brook University’s monoclonal antibody technology is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the Stony Brook University team, you can schedule a time directly on their team’s calendar here.

FirstIgnite is supporting the commercialization of Florida International University’s self-healing polymer composite reinforced with graphene foam technology. This technology enhances the properties of shape memory polymers (SMPs) through the addition of graphene foam, which provides increased strength and stress resistance while maintaining flexibility. The graphene foam is infused with SMPs, enabling the material to possess self-healing properties that are mechanically stronger.

This technology is applicable to the reinforcement of aircraft and automotive structures or components. The global aerospace composites market size was worth $31 billion in 2021 and is expected to exceed $54 billion by 2030.

Florida International University’s graphene foam technology is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the Florida International University team, you can schedule a time directly on their team’s calendar here.

FirstIgnite is supporting the commercialization of Florida International University’s ion trap technology, which uses notched electrodes to detect, trap, and sort charged ion particles. By reducing trapping forces on the ring electrode closest to the detector, the technology improves ion sensitivity and efficiency, leading to more accurate results with less signal loss and lower power consumption.

This technology is applicable to commercial ion traps, which are a common type of mass spectrometer. The mass spectrometry market is expected to grow from $4.5 billion in 2022 to $7 billion by 2028.

Florida International University’s ion trap technology is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the Florida International University team, you can schedule a time directly on their team’s calendar here.

FirstIgnite is proud to announce their marketing support for Binghamton University's nanoparticle ink technology, which involves a new copper-gold (CuAu) alloy. This ink can be printed onto a substrate and, without the requirement for any external triggers, become electrically conductive at room temperature. The benefits of this technology include high conductivity and cost-effectiveness. It is also room temperature sinterable.

The potential applications for this technology are numerous, including its use in printed electronics, solar panels, and flexible PCBs. The global market size for printed electronics was $12.25 billion in 2021 and is expected to grow significantly to reach $45.08 billion by 2031.

Binghamton University’s nanoparticle ink technology is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the Binghamton University team, you can schedule a time directly on their team’s calendar here.

FirstIgnite is supporting the commercialization of Binghamton University’s liposomal lidocaine formulation technology, which involves a newly developed topical lidocaine formulation that encapsulates the drug into flexible liposomes. This approach offers enhanced penetration and delivery to the targeted areas, reducing the need for painful injections.

This technology’s applications include the removal of facial tumors, skin tag/mole removal in sensitive areas, facial cosmetic procedures, dental surgery, and skin procedures in infants and children. The global skin cancer treatment market size was worth $8.19 billion in 2019 and is projected to reach $14.55 billion by 2027.

Binghamton University’s liposomal lidocaine formulation technology is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the Binghamton University team, you can schedule a time directly on their team’s calendar here.

FirstIgnite is supporting the commercialization of Idaho National Laboratory’s anomaly detection in video surveillance technology. This technology uses a single image time series representation (SITSR) approach to accurately identify anomalous activity in real-time, through unsupervised learning that is based on hours of unlabeled 'normal' video footage. With full customization capabilities, the technology can be tailored to meet the needs of each user and includes features such as human skeleton tracking through pose tracking, deep recurrent architectures, optical flow, and single frame estimation.

This technology has a wide range of applications, including the ability to identify and localize unprecedented activity in video surveillance footage. As a result, it has the potential to provide benefits to a range of industries and organizations, from airports and gas stations to university campuses, schools, national laboratories, nuclear reactor facilities, electronic exchanges, police departments, national parks, even home security systems. The video surveillance market is projected to grow from $48.7 billion in 2022 to $76.4 billion by 2027.

Idaho National Laboratory’s anomaly detection in video surveillance technology is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the Idaho National Laboratory team, you can schedule a time directly on their team’s calendar here.

FirstIgnite is supporting MaineHealth's antibody therapy for triple-negative breast cancer (TNBC). This technology utilizes humanized anti-programmed cell death protein 1 (anti-PD-1) antibodies to treat TNBC by targeting patient-derived xenograft (PDX) tumor models in humanized mice. Through this research, the use of TNBC PDXs in humanized mice has been demonstrated as an effective approach for exploring the potential of immune-based therapies in cancer treatment.

This technology has the potential to advance the development of new immunotherapies for TNBC and other types of cancer, improving preclinical testing of immune-based therapies for cancer treatment, and could lead to the development of personalized medicine and targeted cancer treatments. The global market for breast cancer therapeutics was valued at $21.58 billion in 2019 and is expected to grow to $55.27 billion by 2027.

The MaineHealth team is seeking companies who have new CPIs (Checkpoint Inhibitors) in development or advance in their development to be tested in the TNBC model at MaineHealth. Is your company the right fit? If you’d be available for a conversation with the MaineHealth team, you can schedule a time directly on their team’s calendar here.

FirstIgnite is supporting the commercialization of Florida International University's PFAS reduction technology. This technology is highly efficient and cost-effective, reducing contamination levels to meet the EPA Health Advisory's desired cleanup level. Additionally, this technology is environmentally friendly and biologically compatible, making it water-soluble.

This technology has a wide range of applications, including environmental remediation of PFAS in water and other media, detection of low-level concentrations of PFAS, and biological remediation of organisms contaminated with PFAS, such as aquatic species and humans. The polyfluoroalkyl substances (PFAS) waste management market is growing, reaching $1.8 billion in 2022, and is projected to reach $2.9 billion by 2031.

Florida International University’s PFAS reduction technology is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the Florida International University team, you can schedule a time directly on their team’s calendar here.

FirstIgnite is supporting the commercialization of Florida International University’s new fluorescent hydrogels for drug delivery technology. This technology utilizes nanoparticles and microparticles that exhibit multi-channel fluorescence properties, setting them apart as a distinctive imaging agent that can be detected by a wide range of instruments. This technology offers numerous advantages, such as excellent biocompatibility, cell uptake and surface functionality, and eliminates the need for extra fluorescent labels. It is also compatible with various instruments, making it a valuable tool in drug delivery technology.

This technology is applicable to targeted drug delivery and image-guided therapy, bio-sensing, in vivo drug monitoring and diagnosis. The global pharmaceutical drug delivery market size was valued at $1,525.16 billion in 2022 and is projected to exceed $2,047.36 billion by 2030.

Florida International University’s fluorescent hydrogels for drug delivery technology is ready for collaboration (licensing, partnerships, industry feedback, etc.). Is your company the right fit? If you’d be available for a conversation with the Florida International University team, you can schedule a time directly on their team’s calendar here.